What are the main side effects of Semaglutide?

Semaglutide side effects and warning signals include Nausea (most common, usually transient), Vomiting, Diarrhea, Constipation, and Abdominal pain.

What evidence level is Semaglutide?

Semaglutide is rated Level A; the listed research status is FDA Approved.

Weight Loss & Metabolic / Level A / FDA Approved / Last reviewed 2026-06-01

Semaglutide Evidence Guide

Semaglutide remains the best-validated GLP-1-only agent: FDA-approved for diabetes, obesity, cardiovascular risk reduction, and now higher-dose Wegovy HD 7.2mg. Tirzepatide beats it on weight loss in direct obesity trials, but semaglutide still has the deepest cardiovascular outcomes record and the broadest GLP-1 evidence base.

Our Take

Best for: Obesity, type 2 diabetes, cardiovascular risk reduction in overweight patients
Evidence grade: Level A
Confidence: High
Starting point: 0.25mg subcutaneous weekly, titrating per Wegovy/Wegovy HD label

Benefits and Evidence

Weight Loss: Level A, includes human evidence - STEP trials demonstrated ~15-17% body weight reduction with 2.4mg weekly dose. Consistent and significant weight loss across multiple large RCTs with thousands of participants.
Blood Sugar Control: Level A, includes human evidence - Robust evidence for HbA1c reduction of 1.5-1.8% in type 2 diabetes. Superior to many existing diabetes medications in head-to-head trials.
Cardiovascular Protection: Level A, includes human evidence - SELECT trial showed 20% reduction in major adverse cardiovascular events. Significant reduction in cardiovascular death, heart attack, and stroke risk.
Kidney Protection: Level B, includes human evidence - FLOW trial demonstrated significant reduction in kidney disease progression in patients with type 2 diabetes and chronic kidney disease.
GI Side Effects: Level A, includes human evidence - Nausea, vomiting, and diarrhea are common side effects, especially during dose escalation. Usually transient but can lead to discontinuation in some patients.

Side Effects and Warnings

Nausea (most common, usually transient)
Vomiting
Diarrhea
Constipation
Abdominal pain
Headache
Fatigue
Injection site reactions

Research Dosage References

Subcutaneous injection (diabetes) - 0.25-1.0 mg - Once weekly - Start at 0.25mg for 4 weeks, escalate to 0.5mg, then 1.0mg (Ozempic).
Subcutaneous injection (weight) - 0.25-2.4 mg - Once weekly - Gradual escalation over 16-20 weeks to target dose of 2.4mg (Wegovy).
Subcutaneous injection (higher-dose weight) - 7.2 mg maintenance - Once weekly - Wegovy HD 7.2mg was FDA-approved on March 19, 2026 for adults with obesity or overweight with at least one weight-related condition; titration follows the approved label.
Oral - 3-14 mg - Once daily - Take on empty stomach with small amount of water. Wait 30 min before eating (Rybelsus).

Mechanism of Action

Semaglutide works through GLP-1 receptor activation: 1. Appetite regulation: Acts on hypothalamic GLP-1 receptors to reduce appetite and increase satiety. 2. Insulin secretion: Stimulates glucose-dependent insulin release from pancreatic beta cells. 3. Glucagon suppression: Reduces glucagon secretion, lowering hepatic glucose output. 4. Gastric emptying: Slows gastric emptying, contributing to reduced food intake and improved glycemic control. 5. Cardiovascular effects: Reduces inflammation and improves endothelial function.

Legal Status

FDA-approved for type 2 diabetes (Ozempic, 2017), chronic weight management (Wegovy, 2021), cardiovascular risk reduction in adults with established CVD and obesity/overweight, and higher-dose Wegovy HD 7.2mg for weight loss and long-term weight maintenance (March 19, 2026). Prescription required.

Primary Sources

Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med, 2021.
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6). N Engl J Med, 2016.
Semaglutide and Cardiovascular Outcomes in Obesity (SELECT). N Engl J Med, 2023.
Two-Year Effects of Semaglutide on Weight (STEP 5). Nat Med, 2022.